Compounded GLP-1 After FDA Shortage Removal: What Changes
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded GLP-1 medications are not the same as brand-name products and may differ in formulation, purity, and potency.
You have been waiting for compounded GLP-1 to become available and affordable. Or you are already on a compounded program and wondering whether it will still be accessible. Now you are hearing about the FDA removing these medications from the drug shortage list. What does that actually mean for you?
The short answer: the rules changed when the shortages ended, and availability is less certain than it was. This guide explains what happened, why it matters, and what you should be thinking about now. Status on this page is as of October 16, 2026, and none of it is legal advice.
Why compounded GLP-1 existed in the first place
Compounded GLP-1 medications became widely available because of a specific feature of federal law. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act set the conditions under which state-licensed pharmacies and FDA-registered outsourcing facilities may compound drugs[6][7]. When a drug is on FDA’s drug shortage list, those conditions allow broader compounding of it, including by outsourcing facilities using bulk drug substance[2][7].
FDA has said semaglutide and tirzepatide injection products were in shortage starting in 2022 due to increased demand[2]. During that time, compounding pharmacies prepared compounded versions under the shortage rules.
That shortage status was the legal basis for compounding these drugs at scale. Once it ended, that basis went with it.
What the FDA did in 2025: Shortage resolution and enforcement
FDA first determined that the tirzepatide injection shortage was resolved on October 2, 2024, re-evaluated that decision, and reissued it on December 19, 2024[2]. FDA said it confirmed with the manufacturer that its stated product availability and manufacturing capacity could meet present and projected national demand[2].
To avoid disrupting patient treatment, FDA gave compounders a period during which it did not intend to take action for violations that depend on the drug being on the shortage list. For state-licensed (503A) pharmacies, that period for tirzepatide ended after a federal court denied a preliminary injunction on March 5, 2025. For outsourcing facilities (503B), it ended on March 19, 2025[2].
FDA has also issued warning letters to stop the distribution of illegally marketed semaglutide and tirzepatide[5].
Semaglutide followed. FDA determined that the semaglutide injection shortage was resolved on February 21, 2025. For 503A pharmacies, the enforcement discretion period ended after April 22, 2025 (a federal court denied a preliminary injunction on April 24, 2025). For 503B outsourcing facilities, it ended on May 22, 2025[2].
Understanding 503A vs 503B: Why the distinction matters
This is where things get complicated. Compounding pharmacies operate under two different regulatory frameworks, and the end of the shortages affects them differently.
503B outsourcing facilities are FDA-registered compounders that can produce larger batches and may compound without a patient-specific prescription[7][8]. Under the law, they generally may not compound from bulk drug substance unless the substance is on FDA’s 503B bulks list or the drug is on FDA’s drug shortage list[2][7]. As of FDA’s April 1, 2026 update, tirzepatide and semaglutide “do not currently appear on the 503B bulks list or on FDA’s drug shortage list”[2].
503A pharmacies are state-licensed compounders that prepare medications for individual patients based on a prescription[6]. They are overseen mainly by state boards of pharmacy. Federal law still allows 503A compounding after a shortage ends, with conditions. One condition is that the pharmacy may not compound, “regularly or in inordinate amounts,” drugs that are essentially copies of a commercially available drug[2][6]. Under the statute, a compounded drug is not “essentially a copy” when a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner[6].
The practical effect is that the legal room for compounding these drugs is narrower than it was during the shortages, and it differs by pharmacy type. Some compounders have stopped preparing GLP-1 medications; others continue. Availability varies by pharmacy and by state.
Current status as of October 2026: Honest about uncertainty
The regulatory situation can still change. Outsourcing facilities challenged FDA’s shortage decisions in federal court, and FDA tied the end of its 503A enforcement discretion to the court’s rulings on preliminary injunction motions, which were denied in 2025[2]. We do not predict the outcome of any pending rule or case.
FDA Shortage Resolution Timeline
FDA’s drug shortage database lists both the semaglutide injection and tirzepatide injection shortages as resolved, as of October 16, 2026[3][4]:
Tirzepatide: FDA first determined the tirzepatide injection shortage was resolved on October 2, 2024, and reissued that decision on December 19, 2024. The enforcement discretion period for 503A state-licensed pharmacies ended after the March 5, 2025 court ruling. The enforcement discretion period for 503B outsourcing facilities ended on March 19, 2025[2].
Semaglutide: FDA determined the semaglutide injection shortage was resolved on February 21, 2025. The enforcement discretion period for 503A pharmacies ended after April 22, 2025. The enforcement discretion period for 503B facilities ended on May 22, 2025[2].
What this means: Once a drug is off the shortage list, the shortage-based legal justification for compounding it at scale is gone. 503B outsourcing facilities face the bulk drug substance limits described above. 503A pharmacies may still compound for individual patients when the section 503A conditions are met[2][6].
Current Availability (October 16, 2026)
Here is what FDA has published, plus what can be said about the market:
- Tirzepatide injection is not on FDA’s drug shortage list; FDA’s resolution decision was reissued on December 19, 2024[2][4].
- Semaglutide injection is not on FDA’s drug shortage list; FDA determined the shortage was resolved on February 21, 2025[2][3].
- FDA says neither drug currently appears on the 503B bulks list, which limits outsourcing facilities from compounding them from bulk drug substance[2].
- State-licensed 503A pharmacies may compound for individual patients within the conditions of section 503A[6].
- Availability of compounded GLP-1 varies by pharmacy and by state.
- As of October 16, 2026, some telehealth programs still offer compounded GLP-1 medications. Continued availability cannot be guaranteed.
If you are on a compounded program, it is reasonable to plan for the possibility that this option changes. No one can promise how long any particular pharmacy or program will continue to offer it.
What to do if compounded access ends
If compounded access becomes harder where you live, you still have options to discuss with the provider you choose.
The first option is to look at brand-name GLP-1 medications through insurance. Some insurance plans cover brand-name GLP-1 medications for weight management, not only for diabetes or heart disease, and coverage varies by plan. If your plan covers a brand-name medication, your out-of-pocket cost may be lower than you expect. Our overview of what insurance covers for weight loss medications explains the common patterns.
If insurance does not cover it, manufacturers run self-pay programs, and manufacturer patient-assistance programs may help people who meet their income and insurance requirements. Our guide to savings and assistance programs walks through these paths.
If medication access becomes difficult, talk with your prescriber about what comes next, including lifestyle approaches. Do not change your dose or schedule on your own; whether a different dose or schedule fits your situation is a decision for your prescriber.
Some research trials enroll people with obesity and weight-related conditions. You can search for studies on ClinicalTrials.gov, and the provider you choose can help you think through whether one makes sense for you.
What to check before using compounded GLP-1 medication
If you are considering a compounded GLP-1 medication, these checks come from FDA’s own guidance and warnings.
- A real prescription. A licensed provider should evaluate you before any medication is prescribed. At most telehealth programs, a licensed provider decides whether a prescription is appropriate. A site that sells semaglutide or tirzepatide with no prescription is a red flag.
- A licensed pharmacy. The medication should come from a state-licensed pharmacy (you can check its license with your state board of pharmacy) or an FDA-registered outsourcing facility, which you can look up on FDA’s list of registered outsourcing facilities[8]. The guide to 503A vs 503B pharmacies explains the difference.
- The form of the active ingredient. FDA has warned that semaglutide sodium and semaglutide acetate are different active ingredients from those used in the approved drugs[5]. Ask which form the pharmacy uses.
- No “research use” products. FDA has warned companies selling semaglutide, tirzepatide, and other GLP-1 products falsely labeled for research purposes or “not for human consumption”[5].
- Adverse event reports. As of May 31, 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes it is not always possible to determine whether an adverse event directly resulted from the drug[5]. Ask how your dose is measured and who to contact with questions.
- Honesty about the rules. Be cautious with any program that promises compounded GLP-1 will be available indefinitely. Availability depends on FDA policy and applicable state and federal pharmacy laws, which may change.
Transformation Health does not accept payment from providers. How we make money.
For more on what separates a safe source from a risky one, read how to choose a safe compounding pharmacy. For the practical “can I still start today” question, see is compounded GLP-1 still available.
The longer view: What happens to GLP-1 access when the shortage era ends
During the shortages, compounded GLP-1 medications gave many people without insurance coverage a cash-pay option. With both shortages resolved, the legal basis for compounding these drugs at scale has narrowed.
This section is about legal status, not about the quality of any particular product. Shortages were the legal mechanism that permitted compounding at scale. With the shortages resolved, that mechanism no longer applies to these drugs.
Coverage rules for weight-loss medications differ across employer, marketplace, Medicaid, and Medicare plans, and they change. Check your own plan’s current coverage rather than relying on general reports.
The takeaway: if you are currently on a compounded GLP-1 program, continued availability is not guaranteed. Plan ahead. Talk with the provider you choose about alternatives. If insurance coverage is possible, look into it now. If patient-assistance programs might apply to you, gather that information. You are not being punished for choosing compounded medications; you are dealing with rules that changed.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedImportant disclosures
This content is for general education and is not medical advice or legal advice. Talk with a licensed provider about your situation.
Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality[1]. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Nothing on this page should be read as claiming they are equivalent.
Regulatory status can change. The status described on this page is as of October 16, 2026, based on FDA’s compounding statement (most recently updated April 1, 2026) and FDA’s drug shortage database[2][3][4]. Check the FDA pages for the current statement. Availability cannot be guaranteed.
Citations
[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality.)
[2] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: shortages since 2022 due to increased demand; tirzepatide and semaglutide shortage resolution dates; manufacturer capacity; 503A and 503B enforcement discretion end dates; March 5, 2025 and April 24, 2025 court rulings; 503A and 503B conditions; bulks list and shortage list status.)
[3] U.S. Food and Drug Administration. “FDA Drug Shortages: Semaglutide Injection.” Status: Resolved. Accessed 2026-10-16. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r
[4] U.S. Food and Drug Administration. “FDA Drug Shortages: Tirzepatide Injection.” Status: Resolved. Accessed 2026-10-16. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r
[5] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: warning letters on illegally marketed semaglutide and tirzepatide; salt-form warning; research-use products; adverse event counts as of May 31, 2026 and causality caveat.)
[6] 21 U.S.C. 353a, Pharmacy compounding (section 503A of the Federal Food, Drug, and Cosmetic Act). https://www.law.cornell.edu/uscode/text/21/353a (Accessed 2026-10-16. Supports: compounding for an identified individual patient based on a prescription; “essentially a copy” limit and definition.)
[7] 21 U.S.C. 353b, Outsourcing facilities (section 503B of the Federal Food, Drug, and Cosmetic Act). https://www.law.cornell.edu/uscode/text/21/353b (Accessed 2026-10-16. Supports: outsourcing facility conditions and bulk drug substance restrictions.)
[8] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Status on this page is as of October 16, 2026. Transformation Health does not accept payment from providers. How we make money.